Skip to main content
Premium Trial:

Request an Annual Quote

We've Got One for 'Unwieldy.' Anyone for 'Streamlined and Successful'?

Derek Lowe has a good post about the future of Pfizer now that its merger with Wyeth is complete, basing some of his thoughts on a post from the Wall Street Journal's Health Blog, which interviewed two R&D honchos at the pharma. "Following a popular trend in the industry, Pfizer will continue to decentralize much of its R&D, which will be spread across 18 different units," the WSJ post says.

Lowe thinks the execs could have been more forthcoming, saying that "what might be refreshing is an admission that big mergers - drag-on-for-months am-I-going-to-still-be-here mergers - come with an acute productivity penalty no matter what." He speculates that what Pfizer will look like in a year is "unwieldy."

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.